The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats

Peptides

Volumn 69, Issue , 2015, Pages 47-55

  Skarbaliene, Jolanta ^a   Secher, Thomas ^b   Jelsing, Jacob ^b   Ansarullah, ^c,e   Neerup, Trine S R ^a,f   Billestrup, Nils ^d   Fosgerau, Keld ^a  

^a Zealand Pharma AS   (Denmark)

^b Gubra ApS   (Denmark)

^c SANFORD RESEARCH   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e TOTAL   (France)

^f Bionor Pharma ASA   (Norway)

Author keywords

Dual agonist; Gastrin; Glucagon like peptide 1; Pancreatic beta cell; Type 2 diabetes; Zucker diabetic fatty rats

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GASTRIN; GASTRIN 17; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; UNCLASSIFIED DRUG; ZP 3022; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; ZP3022;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CELL FRACTIONATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FLUID INTAKE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; ZUCKER DIABETIC FATTY RAT; AGONISTS; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; ZUCKER RAT;

MUS; RATTUS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GASTRINS; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; PEPTIDES; RATS; RATS, ZUCKER;

EID: 84928011579     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2015.03.024     Document Type: Article

References (40)

1. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, and C.J. Paciorek National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 2011 31 40
2. E. Ferrannini The stunned beta cell: a brief history Cell Metab 2010 349 352
3. United Kingdom Prospective Diabetes Study (UKPDS) Group U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group Diabetes 1995 1249 1258
4. J.B. Buse, D.J. Drucker, K.L. Taylor, T. Kim, B. Walsh, and H. Hu DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 2010 1255 1261
5. A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang, and B. Bode Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 2011 348 356
6. C. Toso, M. McCall, J. Emamaullee, S. Merani, J. Davis, and R. Edgar Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture Transpl Int 2010 259 265
7. L. Farilla, H. Hui, C. Bertolotto, E. Kang, A. Bulotta, and U. Di Mario Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats Endocrinology 2002 4397 4408
8. D.Y. Kwon, Y.S. Kim, I.S. Ahn, Kim dS, S. Kang, and S.M. Hong Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats J Pharmacol Sci 2009 361 371
9. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 1999 2270 2276
10. B. Finan, T. Ma, N. Ottaway, T.D. Muller, K.M. Habegger, and K.M. Heppner Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Sci Transl Med 2013 209ra151
11. K. Fosgerau, L. Jessen, J.L. Tolborg, T. Osterlund, K.S. Larsen, and K. Rolsted The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice Diabetes Obes Metab 2013 62 71
12. M. Dufresne, C. Seva, and D. Fourmy Cholecystokinin and gastrin receptors Physiol Rev 2006 805 847
13. M.A. Crouch, I.N. Mefford, and E.U. Wade Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes J Am Board Fam Med 2012 50 54
14. K.D. Hove, K. Faerch, T.B. Bodvarsdottir, A.E. Karlsen, J.S. Petersen, and A. Vaag Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis Diabetes Res Clin Pract 2010 e72 e74
15. S.J. Brand, and P.J. Fuller Differential gastrin gene expression in rat gastrointestinal tract and pancreas during neonatal development J Biol Chem 1988 5341 5347
16. J. Morisset, J. Laine, and T. Mimeau-Worthington Hormonal control of rat fetal pancreas development Biol Neonate 1999 327 336
17. I. Rooman, J. Lardon, and L. Bouwens Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue Diabetes 2002 686 690
18. W.L. Suarez-Pinzon, R.F. Power, Y. Yan, C. Wasserfall, M. Atkinson, and A. Rabinovitch Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice Diabetes 2008 3281 3288
19. W.L. Suarez-Pinzon, J.R. Lakey, and A. Rabinovitch Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice Cell Transplant 2008 631 640
20. W.L. Suarez-Pinzon, and A. Rabinovitch Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice Cell Transplant 2011 1343 1349
21. L.S. Dalboge, D.L. Almholt, T.S. Neerup, N. Vrang, J. Jelsing, and K. Fosgerau The novel GLP-1-gastrin dual agonist, ZP3022, improves glucose homeostasis and increases beta cell mass without affecting islet number in db/db mice J Pharmacol Exp Ther 2014 353 360
22. C.L. Brand, E.D. Galsgaard, D. Tornehave, J. Romer, C.F. Gotfredsen, and K. Wassermann Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats Diabetes Obes Metab 2009 795 803
23. N. Vrang, J. Jelsing, L. Simonsen, A.E. Jensen, I. Thorup, and H. Soeborg The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis Am J Physiol Endocrinol Metab 2012 E253 E264
24. P.J. Larsen, E.M. Wulff, C.F. Gotfredsen, C.L. Brand, J. Sturis, and N. Vrang Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats Diabetes Obes Metab 2008 301 311
25. J. Sturis, C.F. Gotfredsen, J. Romer, B. Rolin, U. Ribel, and C.L. Brand GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics Br J Pharmacol 2003 123 132
26. M. Tamaki, Y. Fujitani, T. Uchida, T. Hirose, R. Kawamori, and H. Watada Combination treatment of db/db mice with exendin-4 and gastrin preserves b-cell mass by stimulating b-cell growth and differentiation J Diabetes Invest 2010 172 183
27. N. Tellez, G. Joanny, J. Escoriza, M. Vilaseca, and E. Montanya Gastrin treatment stimulates beta-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats Endocrinology 2011 2580 2588
28. A. Pick, J. Clark, C. Kubstrup, M. Levisetti, W. Pugh, and S. Bonner-Weir Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat Diabetes 1998 358 364
29. B. Petersen, J. Christiansen, and J.F. Rehfeld Acid secretory potency and elimination of the 15-leucine gastrin-17 analogue in man Scand J Gastroenterol 1981 437 440
30. C. Koole, D. Wootten, J. Simms, C. Valant, R. Sridhar, and O.L. Woodman Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening Mol Pharmacol 2010 456 465
31. A. Pocai, P.E. Carrington, J.R. Adams, M. Wright, G. Eiermann, and L. Zhu Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice Diabetes 2009 2258 2266
32. I. Rooman, J. Lardon, D. Flamez, F. Schuit, and L. Bouwens Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas Gastroenterology 2001 940 949
33. J. Morisset, S. Julien, and J. Laine Localization of cholecystokinin receptor subtypes in the endocine pancreas J Histochem Cytochem 2003 1501 1513
34. J. Buteau, S. Foisy, E. Joly, and M. Prentki Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor Diabetes 2003 124 132
35. Y. Miyazaki, Y. Shinomura, S. Tsutsui, S. Zushi, Y. Higashimoto, and S. Kanayama Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor Gastroenterology 1999 78 89
36. W.L. Suarez-Pinzon, J.R. Lakey, S.J. Brand, and A. Rabinovitch Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass J Clin Endocrinol Metab 2005 3401 3409
37. W.L. Suarez-Pinzon, Y. Yan, R. Power, S.J. Brand, and A. Rabinovitch Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice Diabetes 2005 2596 2601
38. B. Rolin, M.O. Larsen, C.F. Gotfredsen, C.F. Deacon, R.D. Carr, and M. Wilken The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice Am J Physiol Endocrinol Metab 2002 E745 E752
39. P. Clerc, M.G. Coll Constans, H. Lulka, S. Broussaud, C. Guigne, and S. Leung-Theung-Long Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice Endocrinology 2007 1039 1049
40. C.S. Levetan, and S.M. Pierce Distinctions between the islets of mice and men: implications for new therapies for type 1 and 2 diabetes Endocr Pract 2013 301 312